Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Central Nervous System Neoplasms 2 Brain Neoplasms 2 Skin Neoplasms 1 Sarcoma 1 Melanoma 1 Glioma 1 Carcinoma, Squamous Cell 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1

Interventions

Doxorubicin 33 pembrolizumab 16 Gemcitabine 15 eribulin 10 Irinotecan 10 olaratumab 9 Trabectedin 9 pazopanib 8 Docetaxel 8 Injections 7 Cyclophosphamide 7 Nivolumab 6 Fluorouracil 6 anlotinib 5 Temozolomide 5 Ipilimumab 5 Ifosfamide 5 Bevacizumab 5 tazemetostat 4 ridaforolimus 4 Drug Therapy 4 Cetuximab 4 Carboplatin 4 toripalimab 3 surufatinib 3 spartalizumab 3 ganitumab 3 entrectinib 3 conatumumab 3 belinostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma × tozuleristide × Clear all

NCT02464332 2016-05-26

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡